跳至主要内容
临床试验/NCT03548948
NCT03548948已完成不适用

Obesity, Iron Regulation and Colorectal Cancer Risk

University of Illinois at Chicago2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2015年7月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
17
试验地点
2
主要终点
Change in colonic inflammation

研究概览

简要总结

Obesity is an independent risk factor for colorectal cancer (CRC) although the underlying mechanisms have not been elucidated. Dietary nutrients play a key role in both the prevention and promotion of CRC. While iron is an essential nutrient, excess iron is associated with carcinogenesis. Unlike the systemic compartment, the intestinal lumen lacks an efficient system to regulate iron. In conditions when dietary iron malabsorption and intestinal inflammation co-exist, greater luminal iron is associated with increased intestinal inflammation and a shift in the gut microbiota to more pro-inflammatory strains. However, treatments designed to reduce luminal, including diet restriction and chelation, are associated with lower intestinal inflammation and the colonization of protective gut microbes. Obesity is associated with inflammation-induced, hepcidin-mediated, iron metabolism dysfunction characterized by iron deficiency and dietary iron malabsorption. Obesity is also linked to intestinal inflammation. Currently, there is a fundamental gap in understanding how altered iron metabolism impacts CRC risk in obesity.

The investigator's objective is to conduct a crossover controlled feeding trial of: 1) a "Typical American" diet with "high" heme/non-heme iron", 2) a "Typical American" diet with "low" iron, and 3) a Mediterranean diet with "high" non heme iron and examine effects on colonic and systemic inflammation and the gut microbiome.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
55 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Self-identify as Hispanic, African American, or Caucasian.
  • Meet body mass index (BMI > = 30.0 kg/m2) and C-reactive protein (CRP) criteria (> 2.0 mg/dl)
  • Post-menopausal (no menstruation in the past 12 months)
  • Weight stable (< 3% weight change in the past 3 months)
  • Non-smoker
  • No major medical problems
  • Have a working phone
  • No known allergies, intolerance, medical, secular or religious dietary restrictions

排除标准

  • Chronic constipation (less than three stools per week for several months)
  • History or intestinal cancer, inflammatory bowel disease, celiac disease, or malabsorptive bariatric surgery
  • Previous intestinal surgery
  • H pylori infection or taking H2 blockers (e.g., Zantac, Pepcid) /antacids (e.g., Rolaids) more than 3 times per week
  • Significant blood loss or blood donation in past 3 months
  • Active gastrointestinal bleed
  • Any surgery in the past 3 months
  • Hemochromatosis
  • Sickle cell disease
  • Hereditary polyposis
  • Rheumatoid arthritis
  • Type I or Type II diabetes
  • Antibiotic use in the past 2 months
  • Excessive alcohol consumption [> 2 standard alcoholic drinks (12 ounces of beer, 5 ounces of wine, 1 shot of hard liquor) per day]
  • Aspirin use >81 mg/day OR >325 mg/every other day
  • Regularly taking probiotics, fiber supplements, Orlistat (over the counter brand name: Alli), or steroids (inhaled or oral)

研究组 & 干预措施

Plant-based high non-heme iron diet

Other

干预措施: Plant-based high non-heme iron diet (Other)

High heme iron diet

Other

干预措施: High heme iron diet (Other)

Low iron diet

Other

干预措施: Low iron diet (Other)

结局指标

主要结局

Change in colonic inflammation

时间窗: Baseline and post-diet (day 22) for each of the three 3-week diets

Fecal calprotectin, a proxy for colon tissue inflammation, will be measured from stool an calprotectin immunoassay

次要结局

  • Change in systemic inflammation(Baseline and post-diet (day 22) for each of the three 3-week diets)
  • Change in stool microbial community profile at the phylum and genus level(Baseline and post-diet (day 22) for each of the three 3-week diets)
  • Change in serum hepcidin(Baseline and post-diet (day 22) for each of the three 3-week diets)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lisa Tussing-Humphreys

Associate Professor

University of Illinois at Chicago

研究点 (2)

Loading locations...

相似试验

Obesity, Iron Regulation and Colorectal Cancer Risk | 临床试验